ArticleKidney3602026
Targeting α v β 8 Integrin with mAb MEDI8367 Prevents Fibrosis in Preclinical Models of CKD.
Article in Kidney360, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Role of αv Integrins in TGF-β-Mediated Renal Fibrosis.Kidney360 · 2026Article
- Epithelial Integrins Coordinate Cellular Crosstalk Through the Regulation of Cytokines During Tissue Remodeling.International journal of molecular sciences · 2026Review
- Therapeutic monoclonal antibodies for diabetic kidney disease: a narrative review from basic mechanisms to clinical evidence.Frontiers in endocrinology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
key pointsα v β 8 integrin was upregulated in kidney tubules and associated with fibrosis and reduced kidney function in human CKD. MEDI8367 blocked α v β 8-mediated TGFβ activation and reduced fibrosis in mouse unilateral ureteral obstruction model. In diabetic kidney disease mouse models, α v β 8 inhibition improved kidney injury markers and preserved kidney function.
backgroundCKD is a global health issue exacerbated by the rising prevalence of diabetes and obesity. Renal fibrosis, characterized by the accumulation of extracellular matrix proteins, is a critical factor in CKD progression. TGF- β , a key profibrotic cytokine, plays a pivotal role in this process. However, systemic inhibition of TGF- β has been limited by associated toxicities.
methodsThis study explores the role of α v β 8 integrin in renal fibrosis and its potential as a therapeutic target in CKD. We used various preclinical models of CKD, including humanized α v β 8 mice and the db/db uninephrectomy model, to investigate the role of α v β 8 integrin in renal fibrosis. Gene set variation analysis was used to assess fibrotic gene signatures in human kidney biopsies. The therapeutic potential of MEDI8367, a monoclonal antibody targeting α v β 8 integrin, was evaluated in vitro and in vivo .
resultsOur findings demonstrate that α v β 8 integrin is upregulated in the tubulointerstitium of CKD kidneys, particularly in diabetic kidney disease, and correlates with TGF- β activation and renal function decline. MEDI8367 effectively inhibited α v β 8-mediated TGF- β activation in vitro and attenuated murine unilateral ureteral obstruction-induced renal fibrosis. Notably, inhibition of α v β 8 reduced kidney damage and improved kidney function in models of diabetic kidney disease and hypertensive nephropathy.
conclusionsOur study highlights the potential of MEDI8367 to mitigate renal fibrosis and improve kidney function, offering a novel approach to CKD treatment that complements existing therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.